Inhibrx Biosciences Expands Oxford Loan to $500M, Draws $100M, and Issues Warrants
INBX has more than doubled off its 52-week low of $20.55.
Summary
Inhibrx Biosciences expanded its Oxford loan facility to $500M, drew $100M, and issued warrants for 21,457 shares. The debt financing strengthens the balance sheet ahead of key clinical readouts.
Key Events · Financing and Capital Events · INBX
-
Loan Facility Expanded to $500M
The second amendment to the Oxford loan agreement increases the total facility to $500 million, adding $325 million in new capacity. Of that, $100 million was drawn immediately as a Term C Loan.
-
Warrants Issued to Lenders
Lenders received warrants to purchase 21,457 shares at $93.21 per share, representing 2% of the $100 million draw. The warrants are immediately exercisable and expire in 10 years.
-
Additional $225M Available at Lenders' Discretion
Up to $225 million in Term D Loans may be drawn in $50 million increments, subject to lender approval. Future draws would also include warrants equal to 2% of the funded amount.
-
Collateral Pledge Added
As additional collateral under the amended agreement, the company pledged its equity securities in Poplar Therapeutics, Inc.
Analysis · INBX · Life Sciences
By amending its loan agreement with Oxford Finance, Inhibrx Biosciences has expanded the facility to $500 million and drawn $100 million immediately. The deal includes warrants for 21,457 shares at $93.21—a modest equity kicker. This non-dilutive capital extends the runway for its two lead oncology programs, ozekibart and INBRX-106, both of which have generated positive clinical data and are approaching key milestones. The financing removes near-term liquidity risk without heavily diluting existing shareholders.
How filings like this one have moved
In the 30 days to Sep 8, 2026, 30% of the 1942 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INBX was trading at $89.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $20.55 to $155.29. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.